Quantcast

Industry news that matters to you.  Learn more

$1 Million Investment to Launch Grand Challenge to Develop a TDP43 Biomarker

The ALS Association, in partnership with ALS Finding a Cure, is pleased to announce the Grand Challenge to generate a biomarker to track TDP43 aggregation. The successful team(s) with the most developed plan will receive up to a $1 million investment.

The Michael J. Fox Foundation and Intel Join Forces to Improve Parkinson’s Disease Monitoring and Treatment through Advanced Technologies

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Intel Corporation recently announced a collaboration aimed at improving research and treatment for Parkinson’s disease — a neurodegenerative brain disease second only to Alzheimer’s in worldwide prevalence. The collaboration includes a multiphase research study using a new big data analytics platform that detects patterns in participant data collected from wearable technologies used to monitor symptoms. This effort is an important step in enabling researchers and physicians to measure progression of the disease and to speed progress toward breakthroughs in drug development.

Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries

Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

KineMed Announces Agreement with Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies

KineMed, Inc. (www.kinemed.com) recently announced an agreement with Amgen to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases.

The Michael J. Fox Foundation Funds Research to Develop Parkinson’s Blood Test

Research being performed by Durin Technologies, Inc., exploring the development of a novel blood test for Parkinson’s disease was recently awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research.